208 related articles for article (PubMed ID: 24018260)
1. Rapid viral expansion and short drug half-life explain the incomplete effectiveness of current herpes simplex virus 2-directed antiviral agents.
Schiffer JT; Swan DA; Corey L; Wald A
Antimicrob Agents Chemother; 2013 Dec; 57(12):5820-9. PubMed ID: 24018260
[TBL] [Abstract][Full Text] [Related]
2. Detailed analysis of mucosal herpes simplex virus-2 replication kinetics with and without antiviral therapy.
Schiffer JT; Magaret A; Selke S; Corey L; Wald A
J Antimicrob Chemother; 2011 Nov; 66(11):2593-600. PubMed ID: 21865349
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding.
Wald A; Selke S; Warren T; Aoki FY; Sacks S; Diaz-Mitoma F; Corey L
Sex Transm Dis; 2006 Sep; 33(9):529-33. PubMed ID: 16540883
[TBL] [Abstract][Full Text] [Related]
4. Famciclovir reduces viral mucosal shedding in HSV-seropositive persons.
Leone P; Warren T; Hamed K; Fife K; Wald A
Sex Transm Dis; 2007 Nov; 34(11):900-7. PubMed ID: 17538513
[TBL] [Abstract][Full Text] [Related]
5. Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections.
Perry CM; Wagstaff AJ
Drugs; 1995 Aug; 50(2):396-415. PubMed ID: 8521764
[TBL] [Abstract][Full Text] [Related]
6. A review of famciclovir in the management of genital herpes.
Faro S
Infect Dis Obstet Gynecol; 1998; 6(1):38-43. PubMed ID: 9678146
[TBL] [Abstract][Full Text] [Related]
7. The pharmacological profile of famciclovir.
Crumpacker C
Semin Dermatol; 1996 Jun; 15(2 Suppl 1):14-26. PubMed ID: 8840412
[TBL] [Abstract][Full Text] [Related]
8. Rapid localized spread and immunologic containment define Herpes simplex virus-2 reactivation in the human genital tract.
Schiffer JT; Swan D; Al Sallaq R; Magaret A; Johnston C; Mark KE; Selke S; Ocbamichael N; Kuntz S; Zhu J; Robinson B; Huang ML; Jerome KR; Wald A; Corey L
Elife; 2013 Apr; 2():e00288. PubMed ID: 23606943
[TBL] [Abstract][Full Text] [Related]
9. Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials.
Johnston C; Saracino M; Kuntz S; Magaret A; Selke S; Huang ML; Schiffer JT; Koelle DM; Corey L; Wald A
Lancet; 2012 Feb; 379(9816):641-7. PubMed ID: 22225814
[TBL] [Abstract][Full Text] [Related]
10. Current recommendations for the treatment of genital herpes.
Leung DT; Sacks SL
Drugs; 2000 Dec; 60(6):1329-52. PubMed ID: 11152015
[TBL] [Abstract][Full Text] [Related]
11. Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes.
Schiffer JT; Abu-Raddad L; Mark KE; Zhu J; Selke S; Koelle DM; Wald A; Corey L
Proc Natl Acad Sci U S A; 2010 Nov; 107(44):18973-8. PubMed ID: 20956313
[TBL] [Abstract][Full Text] [Related]
12. A randomised placebo-controlled trial to explore the effect of suppressive therapy with acyclovir on genital shedding of HIV-1 and herpes simplex virus type 2 among Zimbabwean sex workers.
Cowan FM; Pascoe SJ; Barlow KL; Langhaug LF; Jaffar S; Hargrove JW; Robinson NJ; Bassett MT; Wilson D; Brown DW; Hayes RJ
Sex Transm Infect; 2008 Dec; 84(7):548-53. PubMed ID: 18684855
[TBL] [Abstract][Full Text] [Related]
13. Recent clinical experience with famciclovir--a "third generation" nucleoside prodrug.
Chakrabarty A; Tyring SK; Beutner K; Rauser M
Antivir Chem Chemother; 2004 Sep; 15(5):251-3. PubMed ID: 15535046
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of N-methanocarbathymidine against genital herpes simplex virus type 2 shedding and infection in guinea pigs.
Bernstein DI; Bravo FJ; Pullum DA; Shen H; Wang M; Rahman A; Glazer RI; Cardin RD
Antivir Chem Chemother; 2015 Feb; 24(1):19-27. PubMed ID: 26149263
[TBL] [Abstract][Full Text] [Related]
15. The effects of daily distress and personality on genital HSV shedding and lesions in a randomized, double-blind, placebo-controlled, crossover trial of acyclovir in HSV-2 seropositive women.
Strachan E; Saracino M; Selke S; Magaret A; Buchwald D; Wald A
Brain Behav Immun; 2011 Oct; 25(7):1475-81. PubMed ID: 21693182
[TBL] [Abstract][Full Text] [Related]
16. Famciclovir suppression of asymptomatic and symptomatic recurrent anogenital herpes simplex virus shedding in women: a randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single-center trial.
Sacks SL
J Infect Dis; 2004 Apr; 189(8):1341-7. PubMed ID: 15073669
[TBL] [Abstract][Full Text] [Related]
17. The effect of daily valacyclovir suppression on herpes simplex virus type 2 viral shedding in HSV-2 seropositive subjects without a history of genital herpes.
Sperling RS; Fife KH; Warren TJ; Dix LP; Brennan CA
Sex Transm Dis; 2008 Mar; 35(3):286-90. PubMed ID: 18157071
[TBL] [Abstract][Full Text] [Related]
18. Comparison of efficacies of famciclovir and valaciclovir against herpes simplex virus type 1 in a murine immunosuppression model.
Field HJ; Tewari D; Sutton D; Thackray AM
Antimicrob Agents Chemother; 1995 May; 39(5):1114-9. PubMed ID: 7625798
[TBL] [Abstract][Full Text] [Related]
19. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes. A randomized, double-blind multicenter trial. Canadian Famciclovir Study Group.
Sacks SL; Aoki FY; Diaz-Mitoma F; Sellors J; Shafran SD
JAMA; 1996 Jul; 276(1):44-9. PubMed ID: 8667538
[TBL] [Abstract][Full Text] [Related]
20. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir.
Wald A; Zeh J; Barnum G; Davis LG; Corey L
Ann Intern Med; 1996 Jan; 124(1 Pt 1):8-15. PubMed ID: 7503497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
